CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Personalis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Personalis Inc
6600 Dumbarton Circle
Phone: (650) 752-1300p:650 752-1300 FREMONT, CA  94555  United States Ticker: PSNLPSNL
Business Summary
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
8071 Medical laboratories
7374 Computer processing and data preparation and processing services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board KarinEastham 74 5/17/2022 9/9/2019
President, Chief Executive Officer, Director Christopher M.Hall 55 3/2/2023 10/31/2022
Chief Financial Officer, Chief Operating Officer, Senior Vice President AaronTachibana 63 3/2/2023 3/1/2019
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Personalis (UK) Ltd.
Personalis UK Limited
PSNL
Shanghai Personalis Biotechnology Co., Ltd.

General Information
Number of Employees: 223 (As of 1/31/2024)
Outstanding Shares: 70,648,084 (As of 10/30/2024)
Shareholders: 60
Stock Exchange: NASD
Federal Tax Id: 275411038
Fax Number: (302) 531-3150


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024